Physician profile
Mark D Cook
NPI 1750379236
$528.79
in general payments reported to CMS, 2019-2025
19 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.89 · 2021: $97.69 · 2022: $93.24 · 2023: $95.98 · 2024: $90.89 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $264 · Education: $34.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.09 |
| Education | $34.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $86.61 | 2019-2024 | |
| Glaxosmithkline, LLC. | $62.43 | 2021-2023 | Bexsero, Shingrix, Pediarix |
| Edwards Lifesciences Corporation | $54.45 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ultragenyx Pharmaceutical INC. | $36.43 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.73 | 2024 | |
| Sanofi Pasteur INC. | $27.67 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.20 | 2022 | |
| Exact Sciences Corporation | $26.65 | 2025 | Cologuard Collection Kit |
| Kyowa Kirin, INC. | $22.84 | 2023 | Crysvita |
| Mylan Specialty L.P. | $21.78 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.62 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.50 | 2025 | Zoryve |
| Seqirus USA INC | $15.59 | 2022 | |
| Merck Sharp & Dohme LLC | $15.48 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.81 | 2024 | Airsupra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $13.50 | 2025 | Tlando |
| Xeris Pharmaceuticals, INC. | $13.47 | 2024 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $12.70 | 2022 | |
| Novo Nordisk INC | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.